Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy

Fan, Yu–Chen; Kuai, Rui; Xu, Yao; Ochyl, Lukasz J.; Irvine, Darrell J.; Moon, James J.

doi:10.1021/acs.nanolett.7b03218

Cited by 189 publications

(140 citation statements)

References 38 publications

Supporting

Mentioning

139

Contrasting

Order By: Relevance

“…[226] Chemotherapy combined with immunotherapy can well relieve the toxicities and also improve its treatment effect. [26,126,228] For example, the TLR9 agonist CpG was loaded into a nanodepot platform (NDP) composed of cationic liposomes and thiolated hyaluronic acid (HA). At the same time, immunoregulatory agents provide a preferable environment to ensure the highly efficient antigen presentation and the activation of APCs and cytotoxic T cells.…”

Section: Combination Of Immunotherapy and Traditional Managementsmentioning

confidence: 99%

“…In the chemoimmunotherapy, low dose chemotherapy is capable of inducing ICD of tumor cells and leading to tumor antigen release, so severe side effects are averted. [26] The CpG-NDP was then conjugated onto the surface of immunogenic DTCs, induced by mitoxantrone, an anthracenedione antitumor agent. [227] Many studies that encapsulate the chemo/immunotherapeutic agents in nanosized drug delivery systems have turned out successful.…”

Section: Combination Of Immunotherapy and Traditional Managementsmentioning

confidence: 99%

See 1 more Smart Citation

Immunomodulatory Nanosystems

et al. 2019

View full text Add to dashboard Cite

Immunotherapy has emerged as an effective strategy for the prevention and treatment of a variety of diseases, including cancer, infectious diseases, inflammatory diseases, and autoimmune diseases. Immunomodulatory nanosystems can readily improve the therapeutic effects and simultaneously overcome many obstacles facing the treatment method, such as inadequate immune stimulation, off‐target side effects, and bioactivity loss of immune agents during circulation. In recent years, researchers have continuously developed nanomaterials with new structures, properties, and functions. This Review provides the most recent advances of nanotechnology for immunostimulation and immunosuppression. In cancer immunotherapy, nanosystems play an essential role in immune cell activation and tumor microenvironment modulation, as well as combination with other antitumor approaches. In infectious diseases, many encouraging outcomes from using nanomaterial vaccines against viral and bacterial infections have been reported. In addition, nanoparticles also potentiate the effects of immunosuppressive immune cells for the treatment of inflammatory and autoimmune diseases. Finally, the challenges and prospects of applying nanotechnology to modulate immunotherapy are discussed.

show abstract

Section: Combination Of Immunotherapy and Traditional Managementsmentioning

confidence: 99%

Section: Combination Of Immunotherapy and Traditional Managementsmentioning

confidence: 99%

Immunomodulatory Nanosystems

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Considering immunostimulatory molecules play a critical role in inducing CTLs activation, the combination of nanoadjuvants with ICD inducers is a promising method for ablation of cancer cells. For example, CpG‐nanoparticles combined with dying tumor cells that are immunogenically treated with mitoxantrone as a whole‐cell vaccine enhance antigen presentation on DCs . Another strategy is codelivery of bioadjuvants with chemical drugs or photothermal agents.…”

Section: Delivery System For Provoking Antitumor Immunitymentioning

confidence: 99%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

109

View full text Add to dashboard Cite

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid‐moving advances of nanoparticle‐based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.

show abstract

“…APCs can then engulf the dying tumor cells, process the antigens, and present them on MHCs to activate tumor‐specific T lymphocytes. An example of this strategy used mitoxantrone to induce ICD in vitro prior to treating mice with the dying tumor cells . To amplify the stimulation signal, the dying cells were also conjugated with multilamellar lipid‐polymer nanoparticles laden with CpG.…”

Section: Biomimetic Anticancer Nanovaccinesmentioning

confidence: 99%

Biomimetic Nanotechnology toward Personalized Vaccines

et al. 2019

View full text Add to dashboard Cite

While traditional approaches for disease management in the era of modern medicine have saved countless lives and enhanced patient well‐being, it is clear that there is significant room to improve upon the current status quo. For infectious diseases, the steady rise of antibiotic resistance has resulted in super pathogens that do not respond to most approved drugs. In the field of cancer treatment, the idea of a cure‐all silver bullet has long been abandoned. As a result of the challenges facing current treatment and prevention paradigms in the clinic, there is an increasing push for personalized therapeutics, where plans for medical care are established on a patient‐by‐patient basis. Along these lines, vaccines, both against bacteria and tumors, are a clinical modality that could benefit significantly from personalization. Effective vaccination strategies could help to address many challenging disease conditions, but current vaccines are limited by factors such as a lack of potency and antigenic breadth. Recently, researchers have turned toward the use of biomimetic nanotechnology as a means of addressing these hurdles. Recent progress in the development of biomimetic nanovaccines for antibacterial and anticancer applications is discussed, with an emphasis on their potential for personalized medicine.

show abstract

Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy

Cited by 189 publications

References 38 publications

Immunomodulatory Nanosystems

Immunomodulatory Nanosystems

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Biomimetic Nanotechnology toward Personalized Vaccines

Contact Info

Product

Resources

About